New Systemic Therapies for the Treatment of Advanced Non-Melanoma Skin Cancers: Which of Your Patients May Benefit?

FACULTY

David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, MA

Vishal Anil Patel, MD
Director of Cutaneous Oncology
Director of Dermatologic Surgery
Associate Professor of Dermatology and Medicine/Oncology
George Washington University School of Medicine and Health Sciences
Washington, DC

PROGRAM OVERVIEW

This enduring activity will investigate the critical role of systemic therapy – including targeted treatment and immunotherapy – in patients with advanced non-melanoma skin cancers (NMSCs) who fail or are ineligible for surgical or radiation therapy. Learners will be able to compare and contrast current and emerging systemic treatment options, describe factors that can help determine when systemic therapy is appropriate, and implement elements of multidisciplinary care to enhance the clinical management of NMSC.

TARGET AUDIENCE

This activity is designed to meet the educational needs of dermatologists, oncologists, and the multidisciplinary care team who care for patients with advanced or metastatic basal cell, or cutaneous squamous cell carcinomas.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

• Justify the use of new systemic therapies with different mechanisms of action for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation
• Recommend approaches to identify and mitigate side effects associated with the mechanisms of action of new systemic therapies for the treatment of patients with advanced NMSCs
• Incorporate risk stratification into routine clinical practice in order to identify patients who may benefit from new systemic therapies for the treatment of advanced NMSCs
• Design management plans in conjunction with interdisciplinary care-based teams for patients with advanced NMSCs not amenable to surgery or radiation

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

NURSES (ANCC) CREDIT DESIGNATION

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

David M. Miller, MD, discloses that he has received consulting fees from Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences, Avstera Therapeutics, and Checkpoint Therapeutics. He has done contracted research for Regeneron, Kartos Therapeutics, and NeoImmune Tech. Dr. Miller has ownership in stock options for Checkpoint Therapeutics and Avstera Therapeutics.

Vishal Anil Patel, MD, discloses that he has received consulting fees from Regeneron, PhD Biosciences and Almirall. He has served on the Speakers Bureau for Regeneron and Sanofi. Dr. Patel has ownership in Science 37, including stock.

All relevant financial relationships have been mitigated.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

• Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, Lead Nurse Planner of Med Learning Group has nothing to disclose.
• Chris Drury, Medical Director of Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
• Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete pre-and-post surveys and evaluation

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making expertise before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

RELEASED DATE: February 17, 2023
EXPIRATION DATE: February 17, 2024

Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.